PLIANT THERAPEUTICS, INC. financial data

Symbol
PLRX on Nasdaq
Location
South San Francisco, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1191% % -17%
Debt-to-equity 34% % 80%
Return On Equity -72% % -46%
Return On Assets -53% % -30%
Operating Margin -78404% % -5328%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 61,449,385 shares 0.98%
Common Stock, Shares, Outstanding 61,449,290 shares 0.99%
Entity Public Float $607,605,287 USD -40%
Common Stock, Value, Issued $6,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 61,406,475 shares 1.1%
Weighted Average Number of Shares Outstanding, Diluted 61,406,475 shares 1.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $0 USD -100%
Research and Development Expense $132,365,000 USD -19%
General and Administrative Expense $53,751,000 USD -7.9%
Operating Income (Loss) $186,116,000 USD 16%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $175,499,000 USD 13%
Earnings Per Share, Basic -2 USD/shares 14%
Earnings Per Share, Diluted -2 USD/shares 14%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $93,732,000 USD 18%
Assets, Current $245,588,000 USD -40%
Property, Plant and Equipment, Net $4,344,000 USD -23%
Operating Lease, Right-of-Use Asset $24,794,000 USD -12%
Other Assets, Noncurrent $392,000 USD -8.2%
Assets $276,600,000 USD -38%
Accounts Payable, Current $485,000 USD -93%
Employee-related Liabilities, Current $6,951,000 USD -17%
Accrued Liabilities, Current $8,173,000 USD -16%
Liabilities, Current $17,624,000 USD -56%
Operating Lease, Liability, Noncurrent $28,231,000 USD -5.1%
Liabilities $76,294,000 USD -24%
Accumulated Other Comprehensive Income (Loss), Net of Tax $34,000 USD -96%
Retained Earnings (Accumulated Deficit) $835,819,000 USD -27%
Stockholders' Equity Attributable to Parent $200,306,000 USD -42%
Liabilities and Equity $276,600,000 USD -38%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $48,864,000 USD -61%
Net Cash Provided by (Used in) Financing Activities $498,000 USD -98%
Net Cash Provided by (Used in) Investing Activities $69,114,000 USD 16%
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 61,449,290 shares 0.99%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $20,748,000 USD -59%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $95,214,000 USD 17%
Interest Paid, Excluding Capitalized Interest, Operating Activities $723,000 USD 44%
Deferred Tax Assets, Valuation Allowance $198,498,000 USD 29%
Deferred Tax Assets, Gross $204,554,000 USD 32%
Operating Lease, Liability $29,418,000 USD
Depreciation $1,760,000 USD -16%
Payments to Acquire Property, Plant, and Equipment $262,000 USD -82%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $176,313,000 USD 11%
Lessee, Operating Lease, Liability, to be Paid $39,251,000 USD -8%
Property, Plant and Equipment, Gross $16,378,000 USD 2.2%
Operating Lease, Liability, Current $1,187,000 USD 269%
Lessee, Operating Lease, Liability, to be Paid, Year Two $5,898,000 USD 34%
Lessee, Operating Lease, Liability, to be Paid, Year One $4,406,000 USD 24%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $9,833,000 USD -22%
Lessee, Operating Lease, Liability, to be Paid, Year Three $7,468,000 USD 27%
Deferred Tax Assets, Operating Loss Carryforwards $94,882,000 USD 21%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $10,239,000 USD 28%
Lessee, Operating Lease, Liability, to be Paid, Year Four $7,468,000 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $30,129,000 USD -21%
Interest Expense $1,401,000 USD 27%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%